Cancer antigen peptide and the use thereof

Details Cancer antigen peptide and the use thereof Cancer antigen peptide and the use thereof

2011-03-08

2011-03-08

Ha, Julie (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S019200, C514S019300, C514S021600, C514S021700, C530S300000, C530S328000

Reexamination Certificate

active

07902143

ABSTRACT:
Novel peptides useful as a therapeutic and/or prophylactic agent of cancers, as well as medical uses thereof, are described. Each of these peptides have a consecutive amino acid sequence within a specific region of YKL-40 antigen expressing on the cell surface of brain tumor cells, that is, within the region aa10-19, aa49-61, aa74-83, aa96-117, aa152-161, aa177-185, aa202-211, aa246-261 or aa326-354, which peptide has an immunity-inducing activity. These peptides are useful for therapy and/or prevention of cancers when administered to a living body, and are useful for inducing T cells which exert cytotoxic activity against cancer cells when used to stimulate the T cells in vitro.

REFERENCES:
patent: 6184204 (2001-02-01), Boots et al.
patent: 6881824 (2005-04-01), Boots et al.
Rudinger J, “Characteristics of the amino acids as components of a peptide hormone sequence,” Peptide Hormones, JA Parsons Edition, University Park Press, Jun. 1976, pp. 1-7.
“Designing Custom Peptides,” from Sigma Genosys, pp. 1-2. Accessed Dec. 16, 2004.
Schinzel R, Drueckes P, “The phosphate recognition site ofEscherichia colimaltodextrin phosphorylase,” FEBS, Jul. 1991, 286(1,2): 125-128.
Berendsen HJC, “A Glimpse of the Holy Grail?” Science, 1998, 282: 642-643.
Voet D, Voet JG, Biochemistry, Second Edition, John Wiley & Sons, Inc., 1995, pp. 235-241.
Ngo JT, Marks J, Karplus M, “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” The Protein Folding Problem and Tertiary Structure Prediction, K. Merc Jr. and S. Le Grand Edition, 1994, pp. 491-495.
Bradley CM, Barrick D, “Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat,” J. Mol. Biol., 2002, 324: 373-386.
Intro to cancer from Merck manual, p. 1. Accessed Mar. 5, 2008.
Clinical aspects of cancer from Merck manual, pp. 1-4. Accessed Mar. 5, 2008.
Auerbach R, Akhtar N, Lewis RL, Shinners BL, “Angiogenesis assays: Problems and pitfalls,” cancer and Metastasis Reviews, 2000, 19: 167-172.
Gura T, “Systems for Identifying New Drugs Are Often Faulty,” Science, 1997, 278: 1041-1042.
Jain RK, “Barriers to Drug Delivery in Solid Tumors,” Scientific American, 1994, 58-65.

Affiliated with

Also associated with

Rating

Cancer antigen peptide and the use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer antigen peptide and the use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer antigen peptide and the use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2645720